Nicotinamide adenine dinucleotide (NAD+) is one of the most studied molecules in cellular metabolism. It serves as a coenzyme in over 500 enzymatic reactions — including those involved in energy production, DNA repair, and mitochondrial function — and acts as a substrate for sirtuins, PARPs, and other NAD+-consuming enzymes. Cellular NAD+ levels decline with age, and this decline has been associated with metabolic, cardiovascular, and neurodegenerative changes in published research.
This biological rationale has driven rapid growth in the NAD+-boosting supplement category, with multiple precursor ingredients now available to formulators: NAD+ itself, nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and reduced nicotinamide adenine dinucleotide (NADH). Each is positioned differently in the market and has distinct specifications, stability profiles, regulatory status, and cost-in-use considerations.
This guide is written for procurement, R&D, and regulatory professionals evaluating NAD+ precursors for new product development or line extension. It compares the four ingredients on the parameters that matter most for B2B decisions: mechanism, specification, stability, regulatory status, and formulation behavior.
NAD+ sits at the center of a salvage pathway that allows cells to recycle nicotinamide (a form of vitamin B3) back into NAD+. The pathway includes several intermediates:
For B2B formulators, the practical implication is that the choice between NR, NMN, and NAD+ depends not only on the desired mechanism story but also on the actual bioavailability, stability, and regulatory position of the specific ingredient in the target market.
Specification: Typically sold as ≥95% HPLC-purity white to off-white powder. Common forms include the free acid and various salt forms (disodium salt, trisodium salt). Sodium salt forms offer improved water solubility, which is relevant for beverage and liquid formulations.
Stability: NAD+ is sensitive to heat, moisture, and acidic pH. In finished products, NAD+ should be formulated in protective matrices (e.g., enteric coatings, encapsulation) to minimize degradation during storage. Shelf life is typically 18–24 months when properly packaged in sealed, light-resistant containers with desiccant.
Regulatory status: In the US, NAD+ is sold as a dietary ingredient but is not FDA-approved as a drug. In the EU, NAD+ is on the Novel Food catalogue with restrictions — its regulatory status varies by member state. In China, NAD+ is regulated as a health food ingredient and requires blue cap (保健食品) registration for finished products making health claims.
Formulation notes: Due to digestive degradation, oral NAD+ is often used in sublingual, effervescent, or enteric-coated delivery forms. The reduced form (NADH) is sometimes preferred in cognitive and energy-positioned products where the reduced coenzyme mechanism is the marketing story.
Specification: NR is most commonly supplied as the chloride salt (NR-CL), typically at ≥98% HPLC purity. NR-CL is a white crystalline powder with good water solubility.
Stability: NR is more stable than NAD+ but still requires careful handling. Moisture-sensitive; should be stored sealed with desiccant. Shelf life is typically 24–36 months in proper packaging.
Regulatory status: In the US, NR was the subject of FDA GRAS notification GRN 624 (and several subsequent approvals for specific suppliers and use levels). In the EU, NR is approved as a Novel Food under Regulation (EU) 2017/2470, with specific maximum use levels in food supplements and other food categories. The EU approval is for the chloride salt form.
Formulation notes: NR has the strongest published human clinical evidence base among NAD+ precursors, including randomized controlled trials showing elevation of NAD+ in blood and tissue following oral supplementation. For B2B formulators targeting the longevity or healthy aging category, NR’s regulatory clarity and clinical evidence make it a strong default choice, particularly for EU and US markets.
Cost-in-use: NR-CL is the most expensive of the NAD+ precursor ingredients at the bulk-ingredient level. Typical commercial use levels in finished supplements are 100–300 mg per serving, so cost-in-use should be calculated against target dose rather than per-kilogram price.
Specification: NMN is typically supplied at ≥98% HPLC purity as a white to off-white powder. Several salt forms (sodium salt, disodium salt) are also available with improved solubility.
Stability: NMN is moderately stable but degrades under heat and high humidity. Stabilized forms and protective packaging are commonly used. Shelf life is typically 18–24 months in proper packaging.
Regulatory status: In the US, NMN’s regulatory status has been the subject of evolving interpretation. As of late 2023, the FDA indicated that NMN may be excluded from the dietary supplement category if it is “authorized for investigation as a new drug” — a position that has created uncertainty in the US market. Several NMN suppliers have responded with GRAS notifications, NDIN filings, or position statements. In the EU, NMN is currently not authorized as a Novel Food, which limits its use in EU food supplements. In Japan and China, NMN is available through specific regulatory pathways.
Formulation notes: For B2B buyers serving the US market, the regulatory uncertainty around NMN warrants a careful review with regulatory counsel before launching NMN-positioned products. For markets where NMN is clearly permitted (e.g., Japan, Canada, Australia, and several other countries outside the US/EU), it can be a cost-effective NAD+ precursor choice.
Cost-in-use: NMN is generally less expensive than NR-CL on a per-kilogram basis, and typical use levels in finished supplements are 100–500 mg per serving.
Specification: NADH is typically supplied as the disodium salt, ≥95% HPLC purity. The reduced form requires careful handling to prevent oxidation to NAD+ during storage.
Stability: NADH is the least stable of the NAD+ precursors in this comparison. It is highly sensitive to heat, light, moisture, and acidic pH. Most commercial NADH products use enteric-coated or protective delivery forms to maintain potency through the digestive tract. Shelf life of bulk NADH is typically 12–18 months in proper packaging.
Regulatory status: NADH is widely available in dietary supplements in the US and EU without novel food restrictions, and it has been used in cognitive and energy products for many years. The regulatory pathway is generally more straightforward than for NR or NMN.
Formulation notes: NADH is most often positioned in cognitive support, energy, and “morning alertness” products. For B2B buyers developing products in these categories, NADH offers a well-established ingredient with consumer recognition. For pure NAD+ boosting claims, NR or NMN are more commonly chosen because the research and marketing story centers on the oxidized NAD+ form.
| Parameter | NAD+ | NR-CL | NMN | NADH |
|---|---|---|---|---|
| Common purity spec | ≥95% | ≥98% | ≥98% | ≥95% |
| Stability (bulk) | Moderate | Good | Moderate | Lower |
| Shelf life (typical) | 18–24 mo | 24–36 mo | 18–24 mo | 12–18 mo |
| US regulatory | Dietary ingredient | GRAS (GRN 624) | Uncertain | Dietary ingredient |
| EU regulatory | Restricted | Novel Food approved | Not approved | Dietary supplement |
| Clinical evidence (oral) | Limited | Strong | Moderate | Moderate |
| Approx. cost/kg (bulk) | High | Highest | High | Moderate |
| Common dose (supplement) | 50–250 mg | 100–300 mg | 100–500 mg | 10–50 mg |
| Best-fit positioning | Sublingual, effervescent | Longevity, healthy aging | Cellular energy (where permitted) | Cognitive, alertness |
Several formulation principles apply across all NAD+ precursors:
NAD+ precursors represent a high-stakes ingredient category where supplier selection has meaningful impact on finished product quality. Key evaluation criteria:
A pre-shipment sample and small pilot order is the most effective way to validate a new supplier before scaling up.
NR-CL currently offers the strongest combination of clinical evidence, regulatory clarity, and stability for B2B buyers targeting the US and EU longevity supplement market. NMN is a cost-effective alternative in markets where it is clearly permitted, but its US regulatory uncertainty requires careful review. NAD+ and NADH have established but narrower positioning — NAD+ in sublingual or effervescent delivery forms, NADH in cognitive and energy products.
A well-considered choice of NAD+ precursor depends on target market, positioning, dose, and delivery format, in addition to cost. Working with a supplier that can provide regulatory documentation, full analytical data, and stability support is essential to launching a successful product in this category.
What is the most bioavailable NAD+ precursor?
Published human clinical studies have most consistently shown that oral nicotinamide riboside (NR) elevates blood and tissue NAD+ levels in a dose-dependent manner. NMN has supporting clinical evidence, though some studies suggest NR may produce more consistent NAD+ elevation. NAD+ itself, when taken orally, is largely broken down to nicotinamide in the digestive tract.
Is NR the same as NMN?
No. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are distinct molecules that differ by one phosphate group. Both are precursors to NAD+ through the cellular salvage pathway, but they enter the pathway at different steps and have different stability, cost, and regulatory profiles.
What is NADH used for in supplements?
NADH is the reduced form of NAD+ and is most commonly used in cognitive support, energy, and alertness-positioned supplements. It has a longer history in the dietary supplement market than NR or NMN, with established consumer recognition particularly in European markets.
Are NAD+ precursors safe?
Published safety reviews by regulatory bodies, including the EFSA opinion on NR and the FDA GRAS determination for NR, support the safety of these ingredients at typical use levels. For NR specifically, EFSA has not set a specific upper limit and concluded that NR is safe at the proposed use levels. As with any new ingredient introduction, manufacturers should conduct their own review of current regulatory status in each target market.
How do I choose between NR, NMN, and NAD+?
For US and EU markets, NR-CL is currently the most straightforward choice from a regulatory and clinical evidence perspective. For markets where NMN is clearly permitted (Japan, Canada, Australia, etc.), NMN can be a more cost-effective alternative. NAD+ and NADH are best suited to specific product formats (sublingual, effervescent, enteric-coated) and positioning (cognitive, energy, sublingual NAD+ delivery).
What dose of NR or NMN is typically used in finished products?
Most published clinical studies on NR use doses of 100–300 mg per day. For NMN, published studies use 100–500 mg per day. Formulators should align finished product dose with the relevant clinical evidence and the regulatory position in the target market.
Mulberry leaf extract standardized to 1-deoxynojirimycin (DNJ) has moved from a niche Asian-market ingredient to a mainstream metabolic-health ingredient in…
For decades, synthetic antioxidants like BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene), and TBHQ (tert-butylhydroquinone) have been the default solution for…
From adaptogens to nootropics, the botanical extract industry is evolving rapidly. Here are 5 trends defining 2026.
